Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease | Zendy

Peter A. McCullough | Zendy; Huiman X. Barnhart | Zendy; Jula K. Inrig | Zendy; Donal Reddan | Zendy; Shelly Sapp | Zendy; Uptal D. Patel | Zendy; Ajay Singh | Zendy; Lynda A. Szczech | Zendy; Robert M. Califf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease

Author(s) -

Peter A. McCullough,

Huiman X. Barnhart,

Jula K. Inrig,

Donal Reddan,

Shelly Sapp,

Uptal D. Patel,

Ajay Singh,

Lynda A. Szczech,

Robert M. Califf

Publication year - 2013

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000351175

Subject(s) - epoetin alfa , medicine , hazard ratio , kidney disease , erythropoietin , proportional hazards model , darbepoetin alfa , renal function , myocardial infarction , stroke (engine) , anemia , surgery , confidence interval , mechanical engineering , engineering

Recombinant erythropoietin has become a routine component of care of patients with chronic kidney disease reducing the need for blood transfusions but raising the risks for cardiovascular events. We undertook this secondary analysis of subjects enrolled in the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial to examine the interrelationships between epoetin-alfa maintenance doses utilized and achieved hemoglobin (Hb) irrespective of treatment target and randomized allocation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research